Paliperidone Articles
Johnson & Johnson’s Invega first antipsychotic for schizoaffective disorder approved in EU
5 January 2011
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
J&J seeking to enlarge paliperidone franchise
16 February 2009
Janssen withdraws EU application for Invega
15 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
J&J's paliperidone LA shows 13-week control
22 December 2008
Paliperidone ER helps schizoaffective disorder
10 November 2008
Delay for J&J's schizophrenia injection
1 September 2008
PDCO recommends PIPs for four drugs
3 March 2008
J&J's 4th-qtr 2007 sales jump 16.6%, EPS up 11%
28 January 2008
Charges hit J&J's third qtr; forecast raised
22 October 2007
Invega signficantly cuts schizophrenia vs Seroquel
22 October 2007
Addendum: Janssen/J&J's Invega
22 October 2007
J&J's 2nd-qtr 2007 net income jumps 9.2%
23 July 2007
J&J's Invega approved in UK for schizophrenia
9 July 2007
Invega gets nod from CHMP
7 May 2007
J&J's 4th qtr 2006 EPS beats analysts' estimate
29 January 2007
J&J schizophrenia drug gets approvable letter
9 October 2006
Paliperidone effective in schizophrenia
24 July 2006
J-C submits paliperidone MAA to EMEA
15 May 2006
FDA receives NDA for J&J paliperidone
12 December 2005
J&J uses Elan technology for paliperidone trial
17 January 2005
Showing 1-30 of 30 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
